» Articles » PMID: 33437355

Role of Azithromycin in Antiviral Treatment: Enhancement of Interferon-dependent Antiviral Pathways and Mitigation of Inflammation May Rely on Inhibition of the MAPK Cascade?

Overview
Journal Am J Transl Res
Specialty General Medicine
Date 2021 Jan 13
PMID 33437355
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Azithromycin is a macrolide-type antibiotic used against a broad range of bacterial infection, such as respiratory tract, skin, ear, eye infections, and sexually transmitted diseases. The ongoing severe acute respiratory syndrome (SARS) mediated by Corona Virus 2 (CoVid19) is a global health concern and various countries witnessed the loss of precious human life. In fall 2020, the absence of specific suitable medication or vaccine is still a major cause of concern to fight the pandemic while different countries have already started using their own medication and available resources to save the life of their citizens. At the present, in many countries around the world, we witnessed the use of the antibiotic azithromycin towards the medication of CoVid19; even its effect on anti CoVid19 is still controversial. This mini review aims to address whether azithromycin can affect molecular pathway involved in inflammatory immunity upon viral infection, to find out the rationale behind the use of azithromycin in the treatment of CoVid19. Overall, the data show that the mechanism of action of azithromycin in viral infection may be dependent on a global amplification of the interferon-dependent pathways mediating antiviral responses, leading to a reduction of viral replication, together with a strong impairment of the inflammatory pathways, relying on MAPK cascade inactivation.

Citing Articles

Discerning the role of polymyxin B nonapeptide in restoring the antibacterial activity of azithromycin against antibiotic-resistant .

Al-Marzooq F, Ghazawi A, Tariq S, Daoud L, Collyns T Front Microbiol. 2022; 13:998671.

PMID: 36212888 PMC: 9532765. DOI: 10.3389/fmicb.2022.998671.


A determination of pan-pathogen antimicrobials?.

Prathapan P Med Drug Discov. 2022; 14:100120.

PMID: 35098103 PMC: 8785259. DOI: 10.1016/j.medidd.2022.100120.


Perception, Attitude, and Confidence of Physicians About Antimicrobial Resistance and Antimicrobial Prescribing Among COVID-19 Patients: A Cross-Sectional Study From Punjab, Pakistan.

Hayat K, Ul Mustafa Z, Ikram M, Ijaz-Ul-Haq M, Noor I, Rasool M Front Pharmacol. 2022; 12:794453.

PMID: 35058779 PMC: 8763689. DOI: 10.3389/fphar.2021.794453.


Computational anti-COVID-19 drug design: progress and challenges.

Wang J, Zhang Y, Nie W, Luo Y, Deng L Brief Bioinform. 2021; 23(1).

PMID: 34850817 PMC: 8690229. DOI: 10.1093/bib/bbab484.

References
1.
Retallack H, Di Lullo E, Arias C, Knopp K, Laurie M, Sandoval-Espinosa C . Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A. 2016; 113(50):14408-14413. PMC: 5167169. DOI: 10.1073/pnas.1618029113. View

2.
Ikegaya S, Inai K, Iwasaki H, Naiki H, Ueda T . Azithromycin reduces tumor necrosis factor-alpha production in lipopolysaccharide-stimulated THP-1 monocytic cells by modification of stress response and p38 MAPK pathway. J Chemother. 2009; 21(4):396-402. DOI: 10.1179/joc.2009.21.4.396. View

3.
Schogler A, Kopf B, Edwards M, Johnston S, Casaulta C, Kieninger E . Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J. 2014; 45(2):428-39. DOI: 10.1183/09031936.00102014. View

4.
Oldenburg C, Doan T . Azithromycin for severe COVID-19. Lancet. 2020; 396(10256):936-937. PMC: 7833672. DOI: 10.1016/S0140-6736(20)31863-8. View

5.
Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M . Multiple control of interleukin-8 gene expression. J Leukoc Biol. 2002; 72(5):847-55. View